Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Girling, J.; Knight, C.L.; Chappell, L. Intrahepatic cholestasis of pregnancy: Green-top Guideline No. 43 June 2022. BJOG Int. J. Obstet. Gynaecol. 2022, 129, E95–E114. [Google Scholar] [CrossRef] [PubMed]
- Lee, R.H.; Greenberg, M.; Metz, T.D.; Pettker, C.M. Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy: Replaces Consult #13, April 2011. Am. J. Obstet. Gynecol. 2021, 224, B2–B9. [Google Scholar] [CrossRef] [PubMed]
- World Gastroenterology Organisation. Intrahepatic Cholestasis of Pregnancy: Even Today a Puzzling Disease of Pregnancy. Available online: https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/intrahepatic-cholestasis-of-pregnancy-even-today-a-puzzling-disease-of-pregnancy (accessed on 20 January 2023).
- Dixon, P.H.; Williamson, C. The pathophysiology of intrahepatic cholestasis of pregnancy. Clin. Res. Hepatol. Gastroenterol. 2016, 40, 141–153. [Google Scholar] [CrossRef] [PubMed]
- Kenyon, A.P.; Tribe, R.M.; Nelson-Piercy, C.; Girling, J.C.; Williamson, C.; Seed, P.T.; Vaughan-Jones, S.; Shennan, A.H. Pruritus in pregnancy: A study of anatomical distribution and prevalence in relation to the development of obstetric cholestasis. Obstet. Med. 2010, 3, 25–29. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, A.L.; Ovadia, C.; Syngelaki, A.; Souretis, K.; Martineau, M.; Girling, J.; Vasavan, T.; Fan, H.M.; Seed, P.T.; Chambers, J.; et al. Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: Case–control and cohort study. BJOG Int. J. Obstet. Gynaecol. 2021, 128, 1635–1644. [Google Scholar] [CrossRef] [PubMed]
- Girling, J.C.; Dow, E.; Smith, J.H. Liver function tests in pre-eclampsia: Importance of comparison with a reference range derived for normal pregnancy. BJOG Int. J. Obstet. Gynaecol. 1997, 104, 246–250. [Google Scholar] [CrossRef] [PubMed]
- Ovadia, C.; Seed, P.T.; Sklavounos, A.; Geenes, V.; Di Ilio, C.; Chambers, J.; Kohari, K.; Bacq, Y.; Bozkurt, N.; Brun-Furrer, R.; et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: Results of aggregate and individual patient data meta-analyses. Lancet 2019, 393, 899–909. [Google Scholar] [CrossRef] [PubMed]
- Chappell, L.C.; Bell, J.L.; Smith, A.; Linsell, L.; Juszczak, E.; Dixon, P.H.; Chambers, J.; Hunter, R.; Dorling, J.; Williamson, C.; et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): A randomised controlled trial. Lancet 2019, 394, 849–860. [Google Scholar] [CrossRef] [PubMed]
- Nowacka, U.; Kozlowski, S.; Januszewski, M.; Sierdzinski, J.; Jakimiuk, A.; Issat, T. COVID-19 Pandemic-Related Anxiety in Pregnant Women. Int. J. Environ. Res. Public Health 2021, 18, 7221. [Google Scholar] [CrossRef] [PubMed]
- Nowacka, U.; Malarkiewicz, P.; Sierdzinski, J.; Januszaniec, A.; Kozłowski, S.; Issat, T. COVID-19 Vaccination Status among Pregnant and Postpartum Women—A Cross-Sectional Study on More Than 1000 Individuals. Vaccines 2022, 10, 1179. [Google Scholar] [CrossRef] [PubMed]
- Galang, R.R.; Chang, K.P.; Strid, P.; Snead, M.C.; Woodworth, K.R.; House, L.D.; Perez, M.M.; Barfield, W.D.; Meaney-Delman, D.; Jamieson, D.J.; et al. Severe Coronavirus Infections in Pregnancy: A Systematic Review. Obstet. Gynecol. 2020, 136, 262–272. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Xiao, S. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications. J. Med. Virol. 2020, 92, 1491–1494. [Google Scholar] [CrossRef] [PubMed]
- Nardo, A.D.; Schneeweiss-Gleixner, M.; Bakail, M.; Dixon, E.D.; Lax, S.F.; Trauner, M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021, 41, 20–32. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Liu, S.; Liu, H.; Li, W.; Lin, F.; Jiang, L.; Li, X.; Xu, P.; Zhang, L.; Zhao, L.; et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J. Hepatol. 2020, 73, 807–816. [Google Scholar] [CrossRef] [PubMed]
- Hartl, L.; Haslinger, K.; Angerer, M.; Semmler, G.; Schneeweiss-Gleixner, M.; Jachs, M.; Simbrunner, B.; Bauer, D.J.M.; Eigenbauer, E.; Strassl, R.; et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. J. Hepatol. 2022, 76, 1563–1575. [Google Scholar] [CrossRef] [PubMed]
- D’Ambrosi, F.; Di Maso, M.; Viscardi, A.; Ossola, M.W.; Soldavini, C.M.; Cetera, G.E.; Erra, R.; Ferrazzi, E. Serum hepatic biomarkers in women with obstetric cholestasis and a concurrent SARS-CoV-2 infection. J. Obstet. Gynaecol. Res. 2022, 48, 2713–2720. [Google Scholar] [CrossRef] [PubMed]
- Makhija, N.; Tayade, S.; Thatere, U. Gravidic Intrahepatic Cholestasis with Concurrent COVID-19 Infection. Cureus 2022, 14, e29326. [Google Scholar] [CrossRef] [PubMed]
- Bomba-Opoń, D.; Drews, K.; Huras, H.; Laudański, P.; Paszkowski, T.; Wielgoś, M.; Fuchs, T.; Pomorski, M.; Zimmer, M. Rekomendacje Polskiego Towarzystwa Ginekologów i Położników dotyczące indukcji porodu. Aktualizacja 2021 [Polish Society of Gynecologists and Obstetricians recommendations for labor induction. 2021 update]. RAK PIERSI 2021, 86. [Google Scholar]
- Cai, Q.; Huang, D.; Yu, H.; Zhu, Z.; Xia, Z.; Su, Y.; Li, Z.; Zhou, G.; Gou, J.; Qu, J.; et al. COVID-19: Abnormal liver function tests. J. Hepatol. 2020, 73, 566–574. [Google Scholar] [CrossRef] [PubMed]
- Bertolini, A.; Van De Peppel, I.P.; Bodewes, F.A.; Moshage, H.; Fantin, A.; Farinati, F.; Fiorotto, R.; Jonker, J.W.; Strazzabosco, M.; Verkade, H.J.; et al. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology 2020, 72, 1864–1872. [Google Scholar] [CrossRef]
- Choudhary, A.; Singh, V.; Bharadwaj, M. Maternal and Neonatal Outcomes in Pregnant Women With SARS-CoV-2 Infection Complicated by Hepatic Dysfunction. Cureus 2022, 14, e25347. [Google Scholar] [CrossRef] [PubMed]
- Hay, J.E. Liver disease in pregnancy. J. Hepatol. 2008, 47, 1067–1076. [Google Scholar] [CrossRef] [PubMed]
- Czeisler, M.; Marynak, K.; Clarke, K.E.; Salah, Z.; Shakya, I.; Thierry, J.M.; Ali, N.; McMillan, H.; Wiley, J.F.; Weaver, M.D.; et al. Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns—United States, June 2020. MMWR Morb. Mortal. Wkly. Rep. 2022, 69, 1250–1257. [Google Scholar] [CrossRef] [PubMed]
- Fida, R.; Wahab, S.; Naz, A.; Shah, M.; Khan, A. Impact of COVID-19 on the Prevalence of Intrahepatic Cholestasis of Pregnancy. Pakistan J. Med. Health Sci. 2023, 17, 543–545. [Google Scholar] [CrossRef]
- Holden, M.G.; Schmiech, K.V.; Telleria, M.M.; Sun, X.; Bender, W.R.; Karjane, N.W. COVID-stasis of Pregnancy: An Increased Prevalence of COVID-19 in Patients with Cholestasis. Am. J. Perinatol. 2023. [Google Scholar] [CrossRef] [PubMed]
- Soffer, M.D.; Lagon, E.P.; James, K.E.; Li, D.K.; Schaefer, E.A.; Duzyj, C.M. 1150 Intrahepatic cholestasis of pregnancy (IHCP) during the era of COVID-19. Am. J. Obstet. Gynecol. 2021, 224, S709. [Google Scholar] [CrossRef]
- Januszewski, M.; Ziuzia-Januszewska, L.; Kudan, M.; Pluta, K.; Klapaczyński, J.; Wierzba, W.; Maciejewski, T.; Jakimiuk, A.A.; Jakimiuk, A.J. Liver damage profile in COVID-19 pregnant patients. Cell Commun. Signal. 2024, 22, 5. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Mao, B.; Liang, S.; Yang, J.-W.; Lu, H.-W.; Chai, Y.-H.; Wang, L.; Zhang, L.; Li, Q.-H.; Zhao, L.; et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur. Respir. J. 2020, 55, 2001112. [Google Scholar] [CrossRef] [PubMed]
- Lupattelli, A.; Picinardi, M.; Cantarutti, A.; Nordeng, H. Use and Intentional Avoidance of Prescribed Medications in Pregnancy: A Cross-Sectional, Web-Based Study among 926 Women in Italy. Int. J. Environ. Res. Public Health 2020, 17, 3830. [Google Scholar] [CrossRef] [PubMed]
Variant 1 | Variant 2 | ||||||
---|---|---|---|---|---|---|---|
General | Childbirth before the Pandemic | Childbirth during the Pandemic | p-Value for the Difference | No History of COVID-19 | History of COVID-19 | p-Value for the Difference | |
Age (years): median IQR | 32.4 (29.0–36.4) | 32.4 (29.6–36.3) | 32.6 (28.9–36.4) | 0.979 * | 32.5 (29.1–36.4) | 31.3 (28.9–36.5) | 0.571 * |
Primiparity | 101 (51%) | 59 (52%) | 42 (51%) | 0.873 ** | 88 (51%) | 13 (52%) | 0.938 ** |
Diagnosis of ICP—days before the due date | 34 (21–50) | 34 (22–46) | 33 (21–55) | 0.801 * | 33 (21–48.5) | 40 (22–58.0) | 0.118 * |
Twins, N (%) | 16 (7%) | 9 (7%) | 7 (7%) | 0.970 ** | 1 (3%) | 15 (7%) | 0.412 ** |
Gestational diabetes, N (%) | 65 (29%) | 32 (25%) | 33 (32%) | 0.209 ** | 57(28%) | 8(27%) | 0.872 |
Before Pandemic & | % $ | In the Pandemic & | % $ | p Value for the Difference | Without COVID-19 $ | % $ | COVID-19 + $ | % $ | p Value for the Difference | |
---|---|---|---|---|---|---|---|---|---|---|
Number of deliveries | 3397 | 4402 | 0.0013 ** | |||||||
Incidence of ICP | 122 | 3.59% (359/10,000) | 104 | 2.36% (236/10,000) | 201 | 25 | ||||
Moderate ICP ≥ 40 μmol/L | 19 | 0.559% | 16 | 0.36% | 0.1913 ** | 31 | 4 | |||
Mild ICP < 40 μmol/L | 103 | 3.03% | 88 | 2.00% | 0.0035 ** | 170 | 21 | |||
BA (μmol/L) -on admission -maximum | 13.9 18.5 | (9.0–30.0) (10.9–40.9) | 16.9 22.5 | (10.2–31.5) (12.2–44.5) | 0.301 * 0.178 * | 14.6 20.2 | (9.4–31.1) (13.3–42.3) | 15.1 19.5 | (9.6–28.0) 12.6–43.0) | 0.972 * 0.600 * |
ALT (U/l) -on admission -maximum | 132.0 158.0 | (57.0–122.0) (76.0–301.0) | 132.5 154.5 | (65.0–269.0) (86.0–359.0) | 0.833 * 0.522 * | 139.0 157.0 | (65.0–276.0) (84.0–325.0) | 101.0 149.5 | (51.0–215.0) (66.0–288.0) | 0.171 * 0.528 * |
AST (U/l) -on admission -maximum | 83.5 99.0 | (41.0–149.5) (50.5–173.5) | 78.5 95.0 | (47.0–151.0) (51.0–198.0) | 0.793 * 0.631 * | 84.5 100.0 | (41.0–153.5) (57.0–178.0) | 63.5 84.5 | (47.0–94.0) (49.0–176.0) | 0.435 * 0.666 * |
ICP as a main indication for IOL or CS | 67 | 51.5% | 55 | 53.4% | 0.778 ** | 107 | (52.7%) | 15 | (50.0%) | 0.782 ** |
Cesarean section/vacuum assisted/forceps delivery | 58 | 47% | 47 | 48% | 0.905 ** | 88 | (45%) | 17 | 59% | 0.199 ** |
Birth weight (grams) | 3250 | (2800–3600) | 3180 | (2720–3540) | 0.263 * | 3135 | (2650–3750) | 3200 | (2770–3540) | 0.925 * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Malarkiewicz, P.; Nowacka, U.; Januszaniec, A.; Mankiewicz, A.; Kozłowski, S.; Issat, T. Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic. Medicina 2024, 60, 676. https://doi.org/10.3390/medicina60040676
Malarkiewicz P, Nowacka U, Januszaniec A, Mankiewicz A, Kozłowski S, Issat T. Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic. Medicina. 2024; 60(4):676. https://doi.org/10.3390/medicina60040676
Chicago/Turabian StyleMalarkiewicz, Paulina, Urszula Nowacka, Aleksandra Januszaniec, Alicja Mankiewicz, Szymon Kozłowski, and Tadeusz Issat. 2024. "Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic" Medicina 60, no. 4: 676. https://doi.org/10.3390/medicina60040676
APA StyleMalarkiewicz, P., Nowacka, U., Januszaniec, A., Mankiewicz, A., Kozłowski, S., & Issat, T. (2024). Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic. Medicina, 60(4), 676. https://doi.org/10.3390/medicina60040676